ArticlePloS one2015

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.

Debby D Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.